A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
Clinical trial NCT04880109 · TERMINATED
Trial details
- NCT number
- NCT04880109
- Sponsor
- Aptabio Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-20
- Primary completion
- 2022-04-28
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.